{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:48Z","timestamp":1791829248625,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":3182,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1074\/jbc.m111.306472","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T00:23:30Z","timestamp":1321662210000},"page":"893-904","source":"Crossref","is-referenced-by-count":244,"title":["Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3\u03b2 by Tideglusib"],"prefix":"10.1016","volume":"287","author":[{"given":"Juan Manuel","family":"Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Monte-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M111.306472_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2011.02.004","article-title":"2011 Alzheimer's disease facts and figures","volume":"7","author":"Alzheimer's Association","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1074\/jbc.M111.306472_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","article-title":"A hundred years of Alzheimer's disease research","volume":"52","author":"Hardy","year":"2006","journal-title":"Neuron"},{"key":"10.1074\/jbc.M111.306472_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid \u03b2-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1074\/jbc.M111.306472_bib4","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1073\/pnas.0900944106","article-title":"Synaptic transmission block by presynaptic injection of oligomeric amyloid \u03b2","volume":"106","author":"Moreno","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M111.306472_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of Tau mediates amyloid-\u03b2 toxicity in Alzheimer's disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1074\/jbc.M111.306472_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1601-183X.2007.00376.x","article-title":"Glycogen synthase kinase-3\u03b2, or a link between amyloid and Tau pathology?","volume":"7","author":"Muyllaert","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1074\/jbc.M111.306472_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.expneurol.2009.09.011","article-title":"GSK3: a possible link between \u03b2 amyloid peptide and Tau protein","volume":"223","author":"Hern\u00e1ndez","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1074\/jbc.M111.306472_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-\u03b2 and Tau\u2013a toxic pas de deux in Alzheimer's disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1074\/jbc.M111.306472_bib9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1074\/jbc.M111.306472_bib10","first-page":"479249","article-title":"Deconstructing GSK-3: The fine regulation of its activity","volume":"2011","author":"Medina","year":"2011","journal-title":"Int. J. Alz. Dis."},{"key":"10.1074\/jbc.M111.306472_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0304-3940(92)90774-2","article-title":"Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of Tau: generation of paired helical filament epitopes and neuronal localisation of the kinase","volume":"147","author":"Hanger","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1074\/jbc.M111.306472_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-5793(93)81066-9","article-title":"Glycogen synthase kinase 3 \u03b2 is identical to Tau protein kinase I generating several epitopes of paired helical filaments","volume":"325","author":"Ishiguro","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1074\/jbc.M111.306472_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-5793(97)00688-1","article-title":"Lithium inhibits Alzheimer's disease-like Tau protein phosphorylation in neurons","volume":"411","author":"Mu\u00f1oz-Monta\u00f1o","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1074\/jbc.M111.306472_bib14","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.0308512100","article-title":"Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses","volume":"101","author":"Blalock","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M111.306472_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1074\/jbc.M111.306472_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010100435","article-title":"The active form of glycogen synthase kinase-3\u03b2 is associated with granulovacuolar degeneration in neurons in Alzheimer's disease","volume":"103","author":"Leroy","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1074\/jbc.M111.306472_bib17","series-title":"Alzheimer's Disease Pathogenesis: Core Concepts, Shifting Paradigms, and Therapeutic Targets","first-page":"197","article-title":"The role of glycogen synthase kinase-3 (GSK-3) in Alzheimer's disease","author":"Medina","year":"2011"},{"key":"10.1074\/jbc.M111.306472_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2121-2-12","article-title":"Glycogen synthase kinase3 \u03b2 phosphorylates serine 33 of p53 and activates p53's transcriptional activity","volume":"2","author":"Turenne","year":"2001","journal-title":"BMC Cell Biol."},{"key":"10.1074\/jbc.M111.306472_bib19","doi-asserted-by":"crossref","first-page":"32619","DOI":"10.1074\/jbc.M109.067785","article-title":"Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis","volume":"284","author":"Wang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M111.306472_bib20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1471-4159.2001.00495.x","article-title":"CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium","volume":"78","author":"Grimes","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1074\/jbc.M111.306472_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cell.2004.11.012","article-title":"GSK-3\u03b2 regulates phosphorylation of CRMP-2 and neuronal polarity","volume":"120","author":"Yoshimura","year":"2005","journal-title":"Cell"},{"key":"10.1074\/jbc.M111.306472_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0960-9822(01)00002-1","article-title":"Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 \u03b2 phosphorylation","volume":"11","author":"Zumbrunn","year":"2001","journal-title":"Curr. Biol."},{"key":"10.1074\/jbc.M111.306472_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nn.2785","article-title":"A\u03b2(1\u201342) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3\u03b2","volume":"14","author":"Jo","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1074\/jbc.M111.306472_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000091044","article-title":"Association between glycogen synthase kinase-3\u03b2 genetic polymorphism and late-onset Alzheimer's disease","volume":"21","author":"Mateo","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1074\/jbc.M111.306472_bib25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archneur.65.10.1368","article-title":"Association of GSK3B with Alzheimer disease and frontotemporal dementia","volume":"65","author":"Schaffer","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1074\/jbc.M111.306472_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.21476","article-title":"Glycogen synthase kinase-3\u03b2 and Tau genes interact in Alzheimer's disease","volume":"64","author":"Kwok","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1074\/jbc.M111.306472_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0404.2008.01128.x","article-title":"Epistasis between Tau phosphorylation regulating genes (CDK5R1 and GSK-3\u03b2) and Alzheimer's disease risk","volume":"120","author":"Mateo","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1074\/jbc.M111.306472_bib28","first-page":"3","article-title":"Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer's disease","volume":"44","author":"Gentles","year":"2009","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1074\/jbc.M111.306472_bib29","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.2174\/138161210793176581","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease","volume":"16","author":"Medina","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1074\/jbc.M111.306472_bib30","first-page":"533","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic","volume":"11","author":"Medina","year":"2008","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1074\/jbc.M111.306472_bib31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm011020u","article-title":"First non-ATP competitive glycogen synthase kinase 3 \u03b2 (GSK-3\u03b2) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease","volume":"45","author":"Martinez","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1074\/jbc.M111.306472_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol Dis."},{"key":"10.1074\/jbc.M111.306472_bib33","first-page":"S147","article-title":"Phase IIA clinical trial on Alzheimer's Disease with NP-12, a GSK-3 inhibitor","volume":"6","author":"del Ser","year":"2010","journal-title":"Alzheimers and Dement."},{"key":"10.1074\/jbc.M111.306472_bib34","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/jm040895g","article-title":"SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors","volume":"48","author":"Martinez","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1074\/jbc.M111.306472_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","article-title":"Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo","volume":"52","author":"Ring","year":"2003","journal-title":"Diabetes"},{"key":"10.1074\/jbc.M111.306472_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem. J."},{"key":"10.1074\/jbc.M111.306472_bib37","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1074\/jbc.M808698200","article-title":"Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3","volume":"284","author":"Gimenez-Cassina","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M111.306472_bib38","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems","first-page":"100","author":"Segel","year":"1975"},{"key":"10.1074\/jbc.M111.306472_bib39","series-title":"Enzyme Kinetics and Mechanism","author":"Cook","year":"2007"},{"key":"10.1074\/jbc.M111.306472_bib40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","article-title":"Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription","volume":"7","author":"Coghlan","year":"2000","journal-title":"Chem. Biol."},{"key":"10.1074\/jbc.M111.306472_bib41","first-page":"201","article-title":"The behavior and significance of slow-binding enzyme inhibitors","volume":"61","author":"Morrison","year":"1988","journal-title":"Adv. Enzymol. Relat. Areas Mol. Biol."},{"key":"10.1074\/jbc.M111.306472_bib42","series-title":"Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis","first-page":"318","author":"Copeland","year":"2000"},{"key":"10.1074\/jbc.M111.306472_bib43","doi-asserted-by":"crossref","first-page":"23790","DOI":"10.1074\/jbc.M101896200","article-title":"Mechanism of Inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by a statine-based peptide","volume":"276","author":"Marcinkeviciene","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M111.306472_bib44","series-title":"Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding","author":"Fersht","year":"1998"},{"key":"10.1074\/jbc.M111.306472_bib45","doi-asserted-by":"crossref","first-page":"11202","DOI":"10.1073\/pnas.91.23.11202","article-title":"Mechanism of selective inhibition of the inducible isoform of prostaglandin G\/H synthase","volume":"91","author":"Copeland","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M111.306472_bib46","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1021\/bi050247e","article-title":"Mechanistic basis of enzyme-targeted drugs","volume":"44","author":"Robertson","year":"2005","journal-title":"Biochemistry"},{"key":"10.1074\/jbc.M111.306472_bib47","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1073\/pnas.0600445103","article-title":"Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides","volume":"103","author":"Schirmer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M111.306472_bib48","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.7164\/antibiotics.52.1086","article-title":"Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK","volume":"52","author":"Zhao","year":"1999","journal-title":"J. Antibiot."},{"key":"10.1074\/jbc.M111.306472_bib49","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1046\/j.1432-1327.2000.01673.x","article-title":"Paullones are potent inhibitors of glycogen synthase kinase-3\u03b2 and cyclin-dependent kinase 5\/p25","volume":"267","author":"Leost","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1074\/jbc.M111.306472_bib50","doi-asserted-by":"crossref","first-page":"24057","DOI":"10.1074\/jbc.273.37.24057","article-title":"p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway","volume":"273","author":"Patrick","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M111.306472_bib51","first-page":"67","article-title":"Determining protein half-lives","volume":"284","author":"Zhou","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1074\/jbc.M111.306472_bib52","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/MCB.02227-06","article-title":"The Wnt pool of glycogen synthase kinase 3\u03b2 is critical for trophic-deprivation-induced neuronal death","volume":"28","author":"Hongisto","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1074\/jbc.M111.306472_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj20031259","article-title":"Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event","volume":"377","author":"Cole","year":"2004","journal-title":"Biochem. J."},{"key":"10.1074\/jbc.M111.306472_bib54","series-title":"Fundamentals of Enzyme Kinetics","first-page":"113","author":"Cornish-Bowden","year":"2004"},{"key":"10.1074\/jbc.M111.306472_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1074\/jbc.M111.306472_bib56","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/cbic.201000352","article-title":"Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance","volume":"11","author":"Kl\u00fcter","year":"2010","journal-title":"ChemBioChem"},{"key":"10.1074\/jbc.M111.306472_bib57","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820533292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820533292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M111.306472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T19:20:30Z","timestamp":1641324030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820533292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0021925820533292"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m111.306472","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}